Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer

Harriet O. Smith, G. L. Goldberg, L. Carol, S. A. Davidson, C. Tomaino, L. Centrilla, C. D. Runowicz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Dose intensification chemotherapy is currently under investigation in ovarian cancer. In order to establish an optimum dose for future colony stimulating factor trials, 16 patients with ovarian cancer were treated with dose-escalation combination carboplatin plus cyclophosphamide chemotherapy without growth factors. The initial carboplatin dose, 300 mg/m2, was increased to a maximum dose of 400 mg/m2. The initial cyclophosphamide dose, 600 mg/m2, was increased to a maximum dose of 1200 mg/m2. Of 10 patients completing 6 cycles, six patients (60%) were escalated to carboplatin 400 mg/m2 and cyclophosphamide 600-1200 mg/m2. Myelosuppression was severe, with all 6 patients requiring platelet and/or packed red blood cell transfusions. Based on these results, carboplatin 400 mg/m2 with cyclophosphamide 600 mg/m2 was selected as the starting dose with hematopoietic growth factors,

Original languageEnglish (US)
Pages (from-to)411-417
Number of pages7
JournalEuropean Journal of Gynaecological Oncology
Volume15
Issue number6
StatePublished - 1994

Fingerprint

Carboplatin
Cyclophosphamide
Drug Therapy
Ovarian Neoplasms
Intercellular Signaling Peptides and Proteins
Colony-Stimulating Factors
Erythrocyte Transfusion
Blood Platelets
Ovarian epithelial cancer

Keywords

  • Carboplatin
  • Chemotherapy
  • Ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Smith, H. O., Goldberg, G. L., Carol, L., Davidson, S. A., Tomaino, C., Centrilla, L., & Runowicz, C. D. (1994). Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer. European Journal of Gynaecological Oncology, 15(6), 411-417.

Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer. / Smith, Harriet O.; Goldberg, G. L.; Carol, L.; Davidson, S. A.; Tomaino, C.; Centrilla, L.; Runowicz, C. D.

In: European Journal of Gynaecological Oncology, Vol. 15, No. 6, 1994, p. 411-417.

Research output: Contribution to journalArticle

Smith, HO, Goldberg, GL, Carol, L, Davidson, SA, Tomaino, C, Centrilla, L & Runowicz, CD 1994, 'Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer', European Journal of Gynaecological Oncology, vol. 15, no. 6, pp. 411-417.
Smith, Harriet O. ; Goldberg, G. L. ; Carol, L. ; Davidson, S. A. ; Tomaino, C. ; Centrilla, L. ; Runowicz, C. D. / Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer. In: European Journal of Gynaecological Oncology. 1994 ; Vol. 15, No. 6. pp. 411-417.
@article{4d00ef5fb3324de0b83a97110e4d9d81,
title = "Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer",
abstract = "Dose intensification chemotherapy is currently under investigation in ovarian cancer. In order to establish an optimum dose for future colony stimulating factor trials, 16 patients with ovarian cancer were treated with dose-escalation combination carboplatin plus cyclophosphamide chemotherapy without growth factors. The initial carboplatin dose, 300 mg/m2, was increased to a maximum dose of 400 mg/m2. The initial cyclophosphamide dose, 600 mg/m2, was increased to a maximum dose of 1200 mg/m2. Of 10 patients completing 6 cycles, six patients (60{\%}) were escalated to carboplatin 400 mg/m2 and cyclophosphamide 600-1200 mg/m2. Myelosuppression was severe, with all 6 patients requiring platelet and/or packed red blood cell transfusions. Based on these results, carboplatin 400 mg/m2 with cyclophosphamide 600 mg/m2 was selected as the starting dose with hematopoietic growth factors,",
keywords = "Carboplatin, Chemotherapy, Ovarian cancer",
author = "Smith, {Harriet O.} and Goldberg, {G. L.} and L. Carol and Davidson, {S. A.} and C. Tomaino and L. Centrilla and Runowicz, {C. D.}",
year = "1994",
language = "English (US)",
volume = "15",
pages = "411--417",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "6",

}

TY - JOUR

T1 - Dose escalation combination carboplatin/cyclophosphamide chemotherapy for epithelial ovarian cancer

AU - Smith, Harriet O.

AU - Goldberg, G. L.

AU - Carol, L.

AU - Davidson, S. A.

AU - Tomaino, C.

AU - Centrilla, L.

AU - Runowicz, C. D.

PY - 1994

Y1 - 1994

N2 - Dose intensification chemotherapy is currently under investigation in ovarian cancer. In order to establish an optimum dose for future colony stimulating factor trials, 16 patients with ovarian cancer were treated with dose-escalation combination carboplatin plus cyclophosphamide chemotherapy without growth factors. The initial carboplatin dose, 300 mg/m2, was increased to a maximum dose of 400 mg/m2. The initial cyclophosphamide dose, 600 mg/m2, was increased to a maximum dose of 1200 mg/m2. Of 10 patients completing 6 cycles, six patients (60%) were escalated to carboplatin 400 mg/m2 and cyclophosphamide 600-1200 mg/m2. Myelosuppression was severe, with all 6 patients requiring platelet and/or packed red blood cell transfusions. Based on these results, carboplatin 400 mg/m2 with cyclophosphamide 600 mg/m2 was selected as the starting dose with hematopoietic growth factors,

AB - Dose intensification chemotherapy is currently under investigation in ovarian cancer. In order to establish an optimum dose for future colony stimulating factor trials, 16 patients with ovarian cancer were treated with dose-escalation combination carboplatin plus cyclophosphamide chemotherapy without growth factors. The initial carboplatin dose, 300 mg/m2, was increased to a maximum dose of 400 mg/m2. The initial cyclophosphamide dose, 600 mg/m2, was increased to a maximum dose of 1200 mg/m2. Of 10 patients completing 6 cycles, six patients (60%) were escalated to carboplatin 400 mg/m2 and cyclophosphamide 600-1200 mg/m2. Myelosuppression was severe, with all 6 patients requiring platelet and/or packed red blood cell transfusions. Based on these results, carboplatin 400 mg/m2 with cyclophosphamide 600 mg/m2 was selected as the starting dose with hematopoietic growth factors,

KW - Carboplatin

KW - Chemotherapy

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0028143976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028143976&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 411

EP - 417

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 6

ER -